A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
about
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaSuberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.An update on the management of chronic lymphocytic leukaemia.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Role of fludarabine in hematological malignancies.Cladribine: not just another purine analogue?Recent advances in chronic lymphocytic leukemia.Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature.Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
P2860
Q28261949-864A47F5-372B-4A4C-8BE0-2785AE5ACA17Q30303153-44412E20-6714-4889-977E-1D380194A925Q30341946-C7FD0032-6072-40C8-AB06-1B95DA1E6E5AQ31033615-7F770D23-7322-423D-B9CF-51C8E04D0A87Q34571439-61FEAA7B-47D4-4A6D-8EAF-800BBC25AEE5Q34992373-F9350FDC-BE81-4F79-B98C-6A350D508666Q36523498-2C55227C-563B-4185-A820-B3D392C5BC65Q37764869-C4E084C5-6E6C-437E-A9C1-A7E26478893AQ37881962-0B48111D-ABE7-4EE5-B4FD-9D2DBE826360Q38664705-8B8221C7-CBA1-406F-A08A-40B2B1369F45Q39025300-358FA330-9D37-4214-A0BC-328523C07AAEQ41356235-FFCD282B-0FE7-4B6A-943C-36E7B8933B93Q46233638-E67A599B-1456-486A-AE69-FDA569F775D5
P2860
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A phase II study of cladribine ...... results from CALGB Study 9211.
@ast
A phase II study of cladribine ...... results from CALGB Study 9211.
@en
type
label
A phase II study of cladribine ...... results from CALGB Study 9211.
@ast
A phase II study of cladribine ...... results from CALGB Study 9211.
@en
prefLabel
A phase II study of cladribine ...... results from CALGB Study 9211.
@ast
A phase II study of cladribine ...... results from CALGB Study 9211.
@en
P2093
P2860
P356
P1433
P1476
A phase II study of cladribine ...... results from CALGB Study 9211.
@en
P2093
Peterson B
Schiffer C
Vardiman JW
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402752
P577
2003-02-01T00:00:00Z
P5875
P6179
1024080572